Protective effect of simvastatin in the cyclophosphamide-induced hemohrragic cystitis in rats

Acta Cirurgica Brasileira

Volumn 25, Issue 1, 2010, Pages 43-46

  Dantas, Anna Carolina Batista ^a   Batista Jr , Francisco Fábio De Araújo ^a   Macedo, Larissa Freitas ^a   Mendes, Mariana Noronha Castro ^a   Azevedo, Ítalo Medeiros ^a   Medeiros, Aldo Cunha ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Cyclophosphamide; Cystitis; Cytokine; Inflammation; Rats; Simvastatin

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; ALKYLATING AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER INJURY; CONTROLLED STUDY; DRUG EFFECT; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; KIDNEY INJURY; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; URETER INJURY; ANIMAL; BLOOD; CHEMICALLY INDUCED; CYSTITIS; DISEASE MODEL; DRUG EFFECTS; HEMORRHAGE; PATHOLOGY; RANDOMIZATION; URINARY TRACT; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; CYSTITIS; CYTOKINES; DISEASE MODELS, ANIMAL; HEMORRHAGE; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SIMVASTATIN; URINARY TRACT;

EID: 76149098830     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/s0102-86502010000100011     Document Type: Article

References (26)

1. Bays H. Statin safety: An overview and assessment of the data-2005. Am J Cardiol. 2006;97:6-26.
2. Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a silhouette trial sub-study. Curr Med Res Opin. 2006;22:343-50.
3. Kanda H, Hamasaki K, Kubo K, Tateishi S, Yonezumi A, Kanda Y, Yamamoto K, Mimura T. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2024-6.
4. Montaner J. Treatment with statins in the acute phase of ischemic stroke. Expert Rev Neurother. 2005;5:211-21.
5. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res. 2006;98:361-9.
6. Rego AC, Araújo Filho I, Damasceno BP, Egito ES, Silveira IA, Brandão-Neto J, Medeiros AC. Simvastatin improves the healing of infected skin wounds of rats. Acta Cir Bras. 2007;22 (Suppl 1):57-63.
7. Souza Neto JL, Araújo Filho I, Rego AC, Dominici VA, Azevedo IM, Egito ES, Brandão-Neto J, Medeiros AC. Effects of simvastatin in abdominal sepsis in rats. Acta Cir Bras. 2006;21(Suppl 4):8-12.
8. Colvin OM: An overview of cyclophosphamide development and clinical applications. Curr Pharm Des. 1999;5:555-60.
9. Hu VY, Malley S, Dattilio A, Folsom JB, Zvara P, Vizzard MA: COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat. Am J Physiol Regul Integr Comp Physiol. 2003;284:R574-85.
10. Ribeiro RA, Freitas HC, Campos MC, Santos CC, Figueiredo FC, Brito GA, Cunha FQ. Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. J Urol. 2002;167:2229-34.
11. Eichel L, Scheidweiler K, Kost J, Shojaie J, Schwarz E, Messing E, Wood R. Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine. Urology. 2001;58:113-8.
12. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426-3.
13. Gray KJ, Engelmann UH, Johnson EH and Fishman IJ. Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J Urol. 1986;136:497-500.
14. Baumann F, Preiss R. Cyclophosphamide and related anticancer drugs. J Chromatogr B Biomed Sci Appl. 2001;764:173-92.
15. Kopterides P, Theodorakopoulou M, Mentzelopoulos S, Armaganidis A. Cyclophosphamide-induced hemorrhagic cystitis successfully treated with conjugated estrogens. Am J Hematol. 2005;80:166-7.
16. Gonzalez RR, Fong T, Belmar N, Saban M, Felsen D, Te A: Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J Urol. 2005; 73:630-4.
17. Lamale LM, Lutgendorf SK, Zimmerman MB, Kreder KJ. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology. 2006;68:702-6.
18. Lotz M, Villiger P, Hugli T, Koziol J, Zuraw BL. Interleukin-6 and interstitial cystitis. J Urol. 1994;152:869-73.
19. Erickson DR, Xie SX, Bhavanandan VP, Wheeler MA, Hurst RE, Demers LM, Kushner L, Keay SK. A comparison of multiple urine markers for interstitial cystitis. J Urol. 2002;167:2461-9.
20. Ballen KK, Becker P, Levebvre K, Emmons R, Lee K, Levy W, Stewart FM, Quesenberry P, Lowry P. Safety and cost of hyperhydration for the prevention of hemorrhagic cystitis in bone marrow transplant recipients. Oncology. 1999;57:287-92.
21. Kanat O, Kurt E, Yalcinkaya U, Evrensel T, Manavoglu O. Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide-induced hemorrhagic cystitis in rats. Indian J Cancer. 2006;43:12-5.
22. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426-3.
23. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl. 2006;7:31-5.
24. Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag. 2007;3:567-77.
25. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000;80:1095-100.
26. Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta. 2005;353:53-60.